🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's recent agreements with Donald Trump are "fundamentally unstable." This stems from revelations that a recently announced deal on drug pricing, which promises zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond vague headline terms outlined by government press releases.

An Agreement in Principle Only

The arrangement concerning medicines, described as a "landmark" achievement, is still an "broad understanding" without a signed legal text. It has been highlighted that the press releases from the UK and US governments describe the deal in markedly contrasting terms. The British version celebrates securing "duty-free access" as a unique achievement, while the American announcement concentrates on the agreement for the NHS to pay higher prices for new medications.

"We face a genuine possibility that the UK government has agreed to terms to raise drug prices in return for nothing more than a verbal promise from President Trump," stated David Henig, a trade policy analyst. "History shows he has form for not following through on agreements."

A Pattern of Unreliability

Worries have been amplified by Washington's action to suspend the high-value digital accord, which was previously described as "a transformative pact" in the bilateral relationship. The US pointed to a failure to advance from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an earlier tariff deal have not been formally signed off by the US, despite a fast-approaching January deadline. "Our understanding is that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Privately, ministers have expressed concerns that the government's deals with Washington are lacking substance. One minister reportedly said the series of agreements as "resting on shaky ground," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "The only thing more surprising than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a reliable partner. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Government figures have sought to reduce the possibility of the US reneging on the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that instability is part and parcel of dealing with the current US leadership. However, they contend that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

However, delays have arisen in carrying out the broader trade deal. Promised quotas on beef exports have failed to be approved, and the commitment to "eliminate duties on UK metals" has not been fulfilled, with tariffs fixed at 25%.

Moving forward, the two sides have agreed to resume talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.